Nymox leaves its fund-raising late again
This article was originally published in Scrip
Executive Summary
For the second year running, Nymox Pharmaceutical, a US biotech firm, has secured commitments from institutional investors just before it ran out of cash. This time it raised $15 million to fund the ongoing Phase III trial of its benign prostatic hyperplasia (BPH) treatment NX-1207.